Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

2.

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R.

Leukemia. 2016 Dec;30(12):2364-2372. doi: 10.1038/leu.2016.136. Epub 2016 May 20.

3.

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells.

Taylor-Kashton C, Lichtensztejn D, Baloglu E, Senapedis W, Shacham S, Kauffman MG, Kotb R, Mai S.

J Cell Physiol. 2016 Dec;231(12):2711-9. doi: 10.1002/jcp.25378. Epub 2016 Apr 8.

4.

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.

De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y, Kauffman MG, Shacham S, Pennati M, Zaffaroni N.

Oncotarget. 2015 May 30;6(15):13119-32.

5.

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.

Breit MN, Kisseberth WC, Bear MD, Landesman Y, Kashyap T, McCauley D, Kauffman MG, Shacham S, London CA.

BMC Vet Res. 2014 Jul 15;10:160. doi: 10.1186/1746-6148-10-160.

6.

XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Cheng Y, Holloway MP, Nguyen K, McCauley D, Landesman Y, Kauffman MG, Shacham S, Altura RA.

Mol Cancer Ther. 2014 Mar;13(3):675-86. doi: 10.1158/1535-7163.MCT-13-0416. Epub 2014 Jan 15.

7.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D.

Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.

8.

"Chopstick" surgery: a novel technique improves surgeon performance and eliminates arm collision in robotic single-incision laparoscopic surgery.

Joseph RA, Goh AC, Cuevas SP, Donovan MA, Kauffman MG, Salas NA, Miles B, Bass BL, Dunkin BJ.

Surg Endosc. 2010 Jun;24(6):1331-5. doi: 10.1007/s00464-009-0769-8. Epub 2009 Dec 24.

PMID:
20033723
9.

Mutations in the thymidine kinase gene that allow expression of the enzyme in quiescent (G0) cells.

Kauffman MG, Rose PA, Kelly TJ.

Oncogene. 1991 Aug;6(8):1427-35.

PMID:
1909430
11.

Isolation of cell cycle fractions by counterflow centrifugal elutriation.

Kauffman MG, Noga SJ, Kelly TJ, Donnenberg AD.

Anal Biochem. 1990 Nov 15;191(1):41-6.

PMID:
2077941
12.

Activation of SV40 DNA replication in vitro by cellular protein phosphatase 2A.

Virshup DM, Kauffman MG, Kelly TJ.

EMBO J. 1989 Dec 1;8(12):3891-8.

Supplemental Content

Loading ...
Support Center